Ichii Mitsuru, Kurajoh Masafumi, Okute Yujiro, Ihara Yasutaka, Imai Takumi, Morioka Tomoaki, Mori Katsuhito, Shoji Tetsuo, Tsujimoto Yoshihiro, Ubai Takanobu, Emoto Masanori
Division of Internal Medicine, Dialysis Center, Inoue Hospital, Suita 564-0053, Japan.
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
J Clin Med. 2022 Oct 27;11(21):6348. doi: 10.3390/jcm11216348.
Coronavirus disease 2019 (COVID-19) vaccination reduces the risk of progression to severe COVID-19 in the general population. To examine that preventive effect in dialysis patients, the association of vaccination status with severe COVID-19 progression was investigated in this retrospective observational study conducted from December 2020 to May 2022 of 100 such patients hospitalized for non-severe COVID-19 at Inoue Hospital (Suita, Japan). Fifty-seven were fully vaccinated, defined as receiving a COVID-19 vaccine second dose at least 14 days prior to the onset of COVID-19, while 43 were not. Among all patients, 13 (13.0%) progressed to severe COVID-19 with a median (interquartile range) time of 6 (2.5-9.5) days, while 87 (87.0%) were discharged after 11 (8-16) days. Kaplan-Meier analysis showed that fully vaccinated patients had a significantly lower rate of progression to severe COVID-19 ( = 0.001, log-rank test). Cox proportional hazard analysis also indicated that full COVID-19 vaccination was significantly associated with reduced instances of progression to severe COVID-19 (hazard ratio 0.104, 95% confidence interval 0.022 to 0.483; = 0.004) after balancing patient background characteristics using an inverse probability of treatment weight method. These results suggest that full vaccination status contributes to reducing the risk of progression from non-severe to severe COVID-19 in dialysis patients.
2019冠状病毒病(COVID-19)疫苗接种可降低普通人群发展为重症COVID-19的风险。为了研究透析患者中的这种预防效果,在2020年12月至2022年5月于日本吹田市井上医院对100例因非重症COVID-19住院的此类患者进行的这项回顾性观察研究中,调查了疫苗接种状况与重症COVID-19进展之间的关联。57例患者完成了疫苗接种,定义为在COVID-19发病前至少14天接种了第二剂COVID-19疫苗,而43例未完成接种。在所有患者中,13例(13.0%)发展为重症COVID-19,中位(四分位间距)时间为6(2.5 - 9.5)天,而87例(87.0%)在11(8 - 16)天后出院。Kaplan-Meier分析显示,完成疫苗接种的患者发展为重症COVID-19的比例显著更低(P = 0.001,对数秩检验)。Cox比例风险分析还表明,在使用治疗权重逆概率方法平衡患者背景特征后,完成COVID-19疫苗接种与重症COVID-19进展实例减少显著相关(风险比0.104,95%置信区间0.022至0.483;P = 0.004)。这些结果表明,完成疫苗接种有助于降低透析患者从非重症COVID-19发展为重症的风险。